Photo from wikipedia
Abstract We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the… Click to show full abstract
Abstract We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.
Keywords:
sotrovimab;
high risk;
real world;
world experience
Journal Title: Open Forum Infectious Diseases
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Open Forum Infectious Diseases
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!